The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with ...

Key Points Exact Sciences has the potential to be a big name in cancer testing and screening in the future. It already has multiple tests, and is working on one that can screen for multiple cancers.

Exact Sciences reports fourth-quarter revenue of $713 million, beating analyst estimates of $701.3 million. Exact Sciences expects full-year 2025 revenue to be in the range of $3.03 billion to $3. ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial ...

Exact Sciences, the maker of at-home colon cancer screening test Cologuard, said it will buy Cambridge, Massachusetts-based Thrive Earlier Detection Corp. for $2.15 billion in cash and stock.

Exact Sciences is looking for talented people who are passionate about fighting cancer. For more information and to view a complete list of job openings, visit the company careers site.

Exact Sciences plans to launch the new product in the second half of 2020. Exact Sciences thinks that it now has a total addressable market of $20 billion.

On March 3, 2020, Exact Sciences announced completion of its acquisition of Paradigm Diagnostics, Inc. and Viomics, Inc., privately held companies based in Phoenix, AZ. According to Exact Sciences ...